CAJ | 학술논문

目的观察细胞因子诱导的杀伤细胞(CIK细胞)联合介入治疗在中晚期肝细胞肝癌中的作用及疗效.方法对77例诊断为中晚期肝细胞肝癌患者进行随机分组治疗,对照组单用肝动脉插管栓塞化疗即单介入(TACE)法,观察组在对照组基础上配合CIK细胞进行免疫治疗.结果治疗后观察组甲胎蛋白(AFP)以及肝功能较对照组显著下降(P<0.01),临床缓解率(CR+PR)亦明显高于对照组(P<0.05).结论 CIK细胞联合介入治疗有较强的抗癌能力,并且可以有效改善功能,提高临床缓解率以及患者的生存质量.
목적관찰세포인자유도적살상세포(CIK세포)연합개입치료재중만기간세포간암중적작용급료효.방법대77례진단위중만기간세포간암환자진행수궤분조치료,대조조단용간동맥삽관전새화료즉단개입(TACE)법,관찰조재대조조기출상배합CIK세포진행면역치료.결과치료후관찰조갑태단백(AFP)이급간공능교대조조현저하강(P<0.01),림상완해솔(CR+PR)역명현고우대조조(P<0.05).결론 CIK세포연합개입치료유교강적항암능력,병차가이유효개선공능,제고림상완해솔이급환자적생존질량.
objective to observe the cel factor induced the kiler cels (CIK cels) infusion interventional treatment for hepatocelular carcinoma (HCC) in middle-late the role and effect. Methods 77 patients diagnosed with middle-late hepatocelular carcinoma patients were randomly divided into the treatment group, use hepatic artery cannula embolism chemotherapy is single intervention (TACE) method, based on the observation group in the control group with CIK cels immunotherapy. Results After treatment observation group alpha-fetoprotein (AFP) and liver function is a significant fal in the control group (P < 0.01), clinical remission rate (CR + PR) also is obviously higher than that of the control group (P < 0.01). Conclusion CIK cels combined interventional therapy have a stronger ability to fight, and can effectively improve the function, improve the clinical remission rate and the patient's quality of life.